Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
HOME > ORGANIZATION
ORGANIZATION
- Sales Rose Only Slightly, but Drug Wholesalers Still Improved Profit Rates in FY2018: JPWA
August 16, 2019
- Experts Talk over Biosimilar Challenges, Chide Unstable Supplies and Indication Gaps
July 19, 2019
- OTC Groups Call for Enhancing Self-Medication Tax Break, Submit Request
July 19, 2019
- Towards 2020 Reform, JPMA Wants Its Three-Pronged Proposal to Resonate with Public
July 17, 2019
- FPMAJ Asks Member Drug Makers to Conduct Self-Inspections to Ensure Stable Supplies
July 11, 2019
- Generic Association Aims to Contribute to Pre-Symptomatic and Preventive Care: New Industry Vision
July 9, 2019
- JPMA Pushing Teleworking for Member Companies
July 5, 2019
- Generic Use Rate at 74.0% in FY2018: JGA
July 1, 2019
- Govt’s 2019 Honebuto Policy Generally in Line with JPMA Views: President
June 28, 2019
- Revisit Comparator Selection Criteria for New Drug Pricing: JPMA
June 28, 2019
- OTC Group Unveils Reform Requests for Self-Medication Tax Break
June 25, 2019
- Further Pricing Discussions Needed for Pricey Products beyond Kymriah: JMA Chief
June 25, 2019
- Health Insurance Coverage Necessary for Risk Reducing Treatments for BRCA Positive Patients: Cancer Bodies
June 21, 2019
- Japan Doctors’ Lobby Braced for Tough Social Security Debate after Election
June 20, 2019
- Generic Share Hits Plateau after Reaching 70%: FPMAJ Pharmacy Survey
June 17, 2019
- Don’t Expand Comparator PMP Removal Rule, Set Deduction Limit for Method II: FPMAJ
June 17, 2019
- Discuss Cost Effectiveness Assessment, Disclosure Ratios Separately: FPMAJ
June 17, 2019
- FPMAJ Calls for Post-Launch Premiums for Add’l Indications, Evidence
June 17, 2019
- Fix Price Maintenance Premium to Make It Fit Its Concept, Revisit Product/Company Criteria: FPMAJ
June 17, 2019
- JPMA Nudges PMDA to Increase Int’l Staffers, Drive Harmonization in Asia
June 12, 2019
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In 2011 the Japanese pharmaceutical industry was rocked when a whistleblower exposed the falsification of trial data for the drug Diovan, the blockbuster blood pressure drug manufactured by pharma giant Novartis. The ensuing investigation led to the arrest of one…